The FDA pauses the research program on a lentivirus-based treatment for a rare neurological condition after a patient developed a bone marrow disorder that could presage leukemia.
The FDA pauses the research program on a lentivirus-based treatment for a rare neurological condition after a patient developed a bone marrow disorder that could presage leukemia.
The FDA pauses the research program on a lentivirus-based treatment for a rare neurological condition after a patient developed a bone marrow disorder that could presage leukemia.
Bobby Thomas and M. Flint Beal | Feb 1, 2011 | 10 min read
The minority of Parkinson’s cases now known to have genetic origins are shedding light on the cellular mechanisms of all the rest, bringing researchers closer to a cause—and perhaps a cure.